Managing asthma in adolescents and adults: 2020 asthma guideline update from the national asthma education and prevention program
10.1001/jama.2020.21974 · doi-reference
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary
10.1164/ajrccm.163.5.2101039 · doi-reference
Fundamentals of aerosol therapy in critical care
10.1186/s13054-016-1448-5 · doi-reference
Influence of aerosol mask design on fugitive aerosol concentrations during nebulization
10.4187/respcare.10578 · doi-reference
Mitigating fugitive aerosols during aerosol delivery via high-flow nasal cannula devices
10.4187/respcare.09589 · doi-reference
Occupational risk factors and asthma among health care professionals
10.1164/rccm.200609-1331oc · doi-reference
Asthma risk and occupation as a respiratory therapist
10.1164/ajrccm/148.3.671 · doi-reference
Risk of transmitting coronavirus disease 2019 during nebulizer treatment: a systematic review
10.1089/jamp.2020.1659 · doi-reference
Reducing aerosol-related risk of transmission in the era of COVID-19: an interim guidance endorsed by the international society of aerosols in medicine
10.1089/jamp.2020.1615 · doi-reference
Characterization of vibrating mesh aerosol generators
10.4209/aaqr.2018.11.0436 · doi-reference
A new cymbal-shaped high power microactuator for nebulizer application
10.1016/j.mee.2009.05.036 · doi-reference
Investigation of droplet size distribution for vibrating mesh atomizers
10.1016/j.jaerosci.2022.106072 · doi-reference
Study on the influencing factors of the atomization rate in a piezoceramic vibrating mesh atomizer
10.3390/app10072422 · doi-reference
Dry powder inhalation for lung delivery in cystic fibrosis
10.3390/pharmaceutics15051488 · doi-reference
Immunohistologic quantification of P. aeruginosa in the tracheobronchial tree from patients with cystic fibrosis
10.3109/15513819509027007 · doi-reference
Immunohistopathologic localization of P. aeruginosa in lungs from patients with cystic fibrosis. Implications for the pathogenesis of progressive lung deterioration
10.1164/ajrccm/140.6.1650 · doi-reference
Performance of the vibrating membrane aerosol generation device: aeroneb micropump nebulizer
10.1089/jam.2007.0622 · doi-reference
Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation
10.1183/09031936.00006211 · doi-reference
The relevance of targeting treatment to small airways in asthma and COPD
10.4187/respcare.07237 · doi-reference
Small airway dysfunction and poor asthma control: a dangerous liaison
10.1186/s12948-021-00147-8 · doi-reference
Can 'extrafine' dry powder aerosols improve lung deposition?
10.1016/j.ejpb.2015.07.016 · doi-reference
Not all asthma inhalers are the same: factors to consider when prescribing an inhaler
10.4104/pcrj.2009.00029 · doi-reference
Risk of pneumonia in obstructive lung disease: a real-life study comparing extra-fine and fine-particle inhaled corticosteroids
10.1371/journal.pone.0178112 · doi-reference
Evaluation of efficacy and safety of flunisolide hydrofluoroalkane for the treatment of asthma
10.1016/s0149-2918(03)80108-x · doi-reference
Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control
10.1002/psp4.12773 · doi-reference
Futility of current urine salbutamol doping control
10.1111/bcp.13619 · doi-reference
Inhaled nucleic acid delivery systems for the treatment of pulmonary interstitial diseases: challenges and opportunities
10.1016/j.apsb.2025.12.047 · doi-reference
Developmental progress and future potential for inhaled biologics in the treatment of respiratory diseases
10.1007/s40265-026-02336-8 · doi-reference
